MX9606635A - Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes. - Google Patents

Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes.

Info

Publication number
MX9606635A
MX9606635A MX9606635A MX9606635A MX9606635A MX 9606635 A MX9606635 A MX 9606635A MX 9606635 A MX9606635 A MX 9606635A MX 9606635 A MX9606635 A MX 9606635A MX 9606635 A MX9606635 A MX 9606635A
Authority
MX
Mexico
Prior art keywords
lipoxygenase
compounds
inflammatory
activity
acting
Prior art date
Application number
MX9606635A
Other languages
English (en)
Inventor
Xiong Cai
Grewal Grewal
Sajjat Hussoin
Aberra Fura
Ralph Scannell
Tesfaye Biftu
Changgeng Qian
Original Assignee
Cytomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/265,656 external-priority patent/US5792776A/en
Priority claimed from US08/390,641 external-priority patent/US6201016B1/en
Priority claimed from US08/454,600 external-priority patent/US5750565A/en
Priority claimed from US08/454,748 external-priority patent/US5703093A/en
Application filed by Cytomed Inc filed Critical Cytomed Inc
Publication of MX9606635A publication Critical patent/MX9606635A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se exponen tetrahidrofuranos, tetrahidrotiofenos, pirrolidona y ciclopentanos que reducen la quimiotaxis y ráfagas respiratorias que conducen a la formacion de radicales de oxígeno dañinos de leucocitos polimorfonucleares durante una respuesta inflamatoria o inmune. Los compuestos de PAF, al inhibir la encima de 5-lipoxigenasa, o al exhibir doble actividad, es decir al actuar tanto como antagonista receptor de PAF como inhibidor de 5-lipoxigenasa. Se ha determinado que la actividad, disponibilidad oral y estabilidad in vivo (por ejemplo, proporcion de glucoronidacion) de la 5-lipoxigenasa puede variar significativamente entre los isomeros opticos de los compuestos expuestos.
MX9606635A 1994-06-27 1995-06-27 Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes. MX9606635A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/265,656 US5792776A (en) 1994-06-27 1994-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/390,641 US6201016B1 (en) 1994-06-27 1995-02-17 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,600 US5750565A (en) 1995-05-25 1995-05-25 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,748 US5703093A (en) 1995-05-31 1995-05-31 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
PCT/US1995/008213 WO1996000212A1 (en) 1994-06-27 1995-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders

Publications (1)

Publication Number Publication Date
MX9606635A true MX9606635A (es) 1997-12-31

Family

ID=27500861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9606635A MX9606635A (es) 1994-06-27 1995-06-27 Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes.

Country Status (18)

Country Link
EP (1) EP0770064B1 (es)
KR (1) KR100276570B1 (es)
CN (1) CN1151125C (es)
AT (1) ATE253564T1 (es)
AU (1) AU703756B2 (es)
BR (1) BR9508196A (es)
CA (1) CA2194064C (es)
CZ (1) CZ372096A3 (es)
DE (1) DE69532077T2 (es)
EE (1) EE9600184A (es)
FI (1) FI965123A (es)
HK (1) HK1004396A1 (es)
HU (1) HUT77773A (es)
MX (1) MX9606635A (es)
NO (1) NO965569L (es)
PL (1) PL317873A1 (es)
RU (1) RU2190607C2 (es)
WO (1) WO1996000212A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
CA2140034A1 (en) 1992-07-13 1994-01-20 Xiong Cai 2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5750565A (en) * 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
AU3370099A (en) * 1998-03-31 1999-10-18 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
CA2342156A1 (en) 1998-07-03 2000-01-13 Andappan Murugaiah Subbaiah Murugaiah Methods for synthesis of substituted tetrahydrofuran compound
EP1094805A4 (en) * 1998-07-03 2002-08-28 Millennium Pharm Inc ALICYCLIC COMPOUNDS WITH SUBSTITUTED OXYGEN ATOM, AND THEIR PREPARATION METHOD
US6255498B1 (en) 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
EP1311269B1 (en) 2000-08-04 2012-02-29 DMI Biosciences, Inc. Method of using diketopiperazines and composition containing them
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
ES2572975T3 (es) 2003-05-15 2016-06-03 Ampio Pharmaceuticals, Inc. Tratamiento de enfermedades mediadas por los linfocitos T
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc METHODS AND THERAPEUTIC COMPOUNDS
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
US9925300B2 (en) 2011-10-10 2018-03-27 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
WO2013063413A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
KR101480674B1 (ko) * 2014-07-03 2015-01-09 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101503647B1 (ko) 2014-07-03 2015-03-18 주식회사 큐리언트 염증성 질환 치료용 약학적 조성물
KR101496095B1 (ko) * 2014-07-04 2015-03-03 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496094B1 (ko) 2014-07-04 2015-02-25 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496096B1 (ko) * 2014-07-17 2015-03-02 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
JP6723222B2 (ja) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 関節病態の治療
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211146A (en) * 1984-02-29 1987-10-30 Merck & Co Inc 2,5-diaryl-tetrahydrothiophene derivatives and pharmaceutical compositions
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
US4604407A (en) * 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
DE3778248D1 (de) * 1986-08-21 1992-05-21 Merck & Co Inc 1,3-diarylcyclopentane und deren abkoemmlinge als paf-antagonisten.
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US4996203A (en) * 1987-12-21 1991-02-26 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
EP0365089A3 (en) * 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
US5175183A (en) * 1989-02-01 1992-12-29 Abbott Laboratories Lipoxygenase inhibiting compounds
US4977146A (en) * 1989-06-08 1990-12-11 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US5037853A (en) * 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9009469D0 (en) * 1990-04-27 1990-06-20 British Bio Technology Compounds
EP0465122A1 (en) * 1990-06-29 1992-01-08 Merck & Co. Inc. Process of making 2,5-diaryl tetrahydrofurans and analogs thereof useful as paf antagonists
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
US5110831A (en) * 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
JPH0730061B2 (ja) * 1991-02-07 1995-04-05 ファイザー製薬株式会社 ヒドロキサム酸誘導体および組成物
US5420164A (en) * 1991-04-04 1995-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Cycloalkylurea compounds
US5183818A (en) * 1991-08-27 1993-02-02 Abbott Laboratories Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme activity
US5169854A (en) * 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5187192A (en) * 1992-03-13 1993-02-16 Abbott Laboratories Cyclobutyl derivatives having lipoxygenase inhibitory activity
US5326787A (en) * 1992-05-12 1994-07-05 Abbott Laboratories Cycloalkyl N-hydroxy derivatives having lipoxygenase inhibitory activity
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
CA2140034A1 (en) * 1992-07-13 1994-01-20 Xiong Cai 2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
TW448144B (en) * 1993-08-19 2001-08-01 Pfizer Phenoxyphenyl cyclopentenyl hydroxyureas

Also Published As

Publication number Publication date
FI965123A0 (fi) 1996-12-19
KR100276570B1 (ko) 2001-02-01
DE69532077T2 (de) 2004-09-02
ATE253564T1 (de) 2003-11-15
FI965123A (fi) 1997-02-26
HK1004396A1 (en) 1998-11-27
AU2914295A (en) 1996-01-19
PL317873A1 (en) 1997-04-28
BR9508196A (pt) 1997-09-02
NO965569D0 (no) 1996-12-23
CA2194064C (en) 2009-03-17
HUT77773A (hu) 1998-08-28
EE9600184A (et) 1997-06-16
EP0770064B1 (en) 2003-11-05
EP0770064A4 (en) 1998-01-14
RU2190607C2 (ru) 2002-10-10
CN1163610A (zh) 1997-10-29
DE69532077D1 (de) 2003-12-11
HU9603611D0 (en) 1997-02-28
AU703756B2 (en) 1999-04-01
WO1996000212A1 (en) 1996-01-04
CN1151125C (zh) 2004-05-26
NO965569L (no) 1997-02-17
CA2194064A1 (en) 1996-01-04
EP0770064A1 (en) 1997-05-02
CZ372096A3 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
HK1004396A1 (en) Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders.
IL114315A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
PL319605A1 (en) Novel benzoxazoles
PL319785A1 (en) Pharmaceutic compositions for treating diseases caused by production of il-6
WO1993000330A3 (en) Azanorbornane derivatives
NO20060719L (no) Substituerte cykloalkylaminderivater som modulatorer av kemokin reseptor aktivitet
BG105177A (en) Novel substituted pyrazole derivatives
AU1996301A (en) Novel heteroaryl-diazabicycloalkanes
WO2003037368A3 (en) Smad7 inhibitors for the treatment of cns diseases
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
HU9500099D0 (en) 2,5-diaryl tetrahydro-thiohenes-furans and analogs for the treatment of inflammatory and immune disorders
NO974320L (no) Fucopeptider
HK1018265A1 (en) Piperazino derivatives as neurokinin antagonists
NO20060112L (no) Imidazolderivater III
AR020327A1 (es) Uso de una cantidad terapeuticamente efectiva de (-)norcisaprida, o una sal farmacologicamente aceptable de la misma, sustancialmente libre de su (+)estereoisomero, para la preparacion de medicamentos.
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents
CA2394230A1 (en) Novel stromelysin inhibitors
MY115877A (en) Cyclopeptolides
HUP9600476A3 (en) Benzothiophene compounds, intermediates, process for their production, their use and compositions containing them
HUP0204116A3 (en) Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene
WO2004056821A3 (en) Quinolizidine derivatives
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2004057328A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)